Be sure to talk to your doctor before introducing new supplements into your regimen or changing current dosages
In two Phase 2 clinical trials covering stasis and pressure ulcers, TB4 accelerated complete wound closure by almost a month in patients who achieved full healing representing one of the most substantial healing acceleration outcomes observed for a peptide compound in a controlled clinical investigation
Available: [3] T
Our products are mainly sold to North America, Europe, South America, Australia and the Middle East and other countries
In September 2023 the FDA placed BPC-157 in Category 2 of its 503A interim bulk-substances policy, citing immunogenicity and peptide-characterization concerns, effectively excluding it from the 503A compounding bulk-substances list
2018;23(12):3305. Zhang Q, Ju Y, Ma Y, Wang T